• The FDA-approved FINEVISION HP trifocal intraocular lens was recently implanted for the first time at Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine.
• Presbyopia-correcting intraocular lens technologies continue to expand the range of vision options available to cataract surgery patients seeking greater visual independence following surgery.

WALTHAM, Mass., July 30, 2026 — BVI, a leading ophthalmic device company, announced that Bascom Palmer Eye Institute, part of UHealth – the University of Miami Health System and the Miller School of Medicine, performed the institution’s first implantation of the FDA-approved FINEVISION HP trifocal intraocular lens (IOL). The procedure marks a milestone in the continued U.S. adoption of one of the most established trifocal platforms in global cataract surgery. Read More

Read More

• BVI announced the first successful U.S. implantations of its FDA-approved FINEVISION® HP trifocal IOL, marking the transition from regulatory clearance to real-world surgical use.
• Five leading cataract and refractive surgeons performed the initial procedures, advancing BVI’s disciplined, surgeon-led rollout of a category-defining trifocal platform with more than 15 years of global clinical use and proven patient outcomes.

WALTHAM, Mass., February 10, 2026 — BVI, a global leader in ophthalmic device innovation, announced the first successful U.S. implantations of its FDA-approved FINEVISION HP hydrophobic trifocal intraocular lens (IOL), marking the long-anticipated arrival of one of the most established trifocal platforms in global cataract surgery and a major milestone following the product’s U.S. regulatory clearance in October 2025. Read More

Waltham, MA., January 19th, 2026 – BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as an advisor to BVI and begin a new role as senior advisor to TPG Capital.  Read More

• Milestone strengthens the company’s leadership in advanced IOL innovation
• FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients
• Proprietary design features anchor the launch of BVI’s expanded U.S. IOL portfolio

WALTHAM, Mass., Oct. 14, 2025 — BVI, a global leader in ophthalmic device innovation, today announced that the U.S. Food and Drug Administration (FDA) has approved its FINEVISION HP trifocal intraocular lens (IOL). This milestone reinforces BVI’s leadership in premium IOLs and expands advanced vision solutions for U.S. patients. Read More